PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Pain (Neuropathic) (Pregabalin - Pain (Neuropathic))
Records returned : 12 (on 21 Nov 2024 at 23:21:07). Return to search results for ' Pain (Neuropathic) '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.07.03
04.07.04
04.08.01
Green (see narrative)
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Gabapentin is preferred due to lower potential for misuse.
Pregabalin capsules more cost effective than tablets
Green (see narrative)
Formulations :
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
04.07.03
Green
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
04.07.03
04.07.04
04.08.01
Green
Formulations :
- Capsules
- Oral solution
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
First line gabapentinoid.
04.07.03
04.07.04
Green
Formulations :
- Oral solution
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Preferred
04.07.02
Green (see narrative)
Formulations :
- Capsules
- Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
Green (see narrative)
Formulations :
- Modified release capsules
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
MR preparations to be prescribed by brand. Marol MR tablets are the locally preferred brand for primary care.
10.03.02
Green (see narrative)
Formulations :
- Cream
ASPH
RSFT
SASH
SABP
Primary Care
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
Red
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
To be initiated by specialist pain care teams only
04.07.03
07.04.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
04.07.03
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
04.07.03
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients